192 related articles for article (PubMed ID: 28866852)
21. Clinical Response to Treatment with Teriparatide in an Adolescent with Osteoporosis-Pseudoglioma Syndrome (OPPG): A Case Report.
Homaei A; Chegini V; Saffari F
Int J Endocrinol Metab; 2022 Apr; 20(2):e121031. PubMed ID: 35993038
[TBL] [Abstract][Full Text] [Related]
22. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
23. Motor function improvement after intravenous pamidronate in osteoporosis pseudoglioma syndrome.
Di Iorgi N; Maghnie M
J Pediatr; 2006 Nov; 149(5):734. PubMed ID: 17095368
[No Abstract] [Full Text] [Related]
24. Osteoporosis-Pseudoglioma in a Mauritanian Child due to a Novel Mutation in LRP5.
Biha N; Ghaber SM; Hacen MM; Collet C
Case Rep Genet; 2016; 2016():9814928. PubMed ID: 26904320
[TBL] [Abstract][Full Text] [Related]
25. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
[TBL] [Abstract][Full Text] [Related]
26. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.
Ai M; Heeger S; Bartels CF; Schelling DK;
Am J Hum Genet; 2005 Nov; 77(5):741-53. PubMed ID: 16252235
[TBL] [Abstract][Full Text] [Related]
27. LRP5, Bone Mass Polymorphisms and Skeletal Disorders.
Littman J; Yang W; Olansen J; Phornphutkul C; Aaron RK
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895195
[TBL] [Abstract][Full Text] [Related]
28. [Bisphosphonate therapy for children and adolescents with primary and secondary osteoporotic diseases].
Semler O; Land C; Schönau E
Orthopade; 2007 Feb; 36(2):146-51. PubMed ID: 17252257
[TBL] [Abstract][Full Text] [Related]
29. [Osteoporosis-pseudoglioma Syndrome: a pediatric case of primary osteoporosis].
Braslavsky D; Scaglia P; Sanguineti N; Aza-Carmona M; Nevado Blanco J; Lapunzina Badia PD; Fernández MDC; Ruiz O; Carmona A; Szlago M; Arberas C; Cassinelli H; Heath K; Rey R; Bergadá I
Arch Argent Pediatr; 2020 Jun; 118(3):e300-e304. PubMed ID: 32470270
[TBL] [Abstract][Full Text] [Related]
30. LRP5-linked osteoporosis-pseudoglioma syndrome mimicking isolated microphthalmia.
Ergun SG; Akay GG; Ergun MA; Perçin EF
Eur J Med Genet; 2017 Mar; 60(3):200-204. PubMed ID: 28111184
[TBL] [Abstract][Full Text] [Related]
31. Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis.
Onwuneme C; Abdalla K; Cassidy N; Hensey O; Ryan S
Arch Dis Child; 2007 Dec; 92(12):1087. PubMed ID: 18032639
[No Abstract] [Full Text] [Related]
32. Exploiting the WNT Signaling Pathway for Clinical Purposes.
Johnson ML; Recker RR
Curr Osteoporos Rep; 2017 Jun; 15(3):153-161. PubMed ID: 28432596
[TBL] [Abstract][Full Text] [Related]
33. Novel mutations in the LRP5 gene in patients with Osteoporosis-pseudoglioma syndrome.
Pekkinen M; Grigelioniene G; Akin L; Shah K; Karaer K; Kurtoğlu S; Ekbote A; Aycan Z; Sağsak E; Danda S; Åström E; Mäkitie O
Am J Med Genet A; 2017 Dec; 173(12):3132-3135. PubMed ID: 29055141
[No Abstract] [Full Text] [Related]
34. Osteoporosis-pseudoglioma syndrome: Report of two cases and a manifesting carrier.
Maltese P; Ziccardi L; Iarossi G; Gusson E; D'Agruma L; Marchini G; Buzzonetti L; Nicoletti A; Benedetti S; Bertelli M
Ophthalmic Genet; 2017; 38(5):473-479. PubMed ID: 28145787
[TBL] [Abstract][Full Text] [Related]
35. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
Aström E; Magnusson P; Eksborg S; Söderhäll S
Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
[TBL] [Abstract][Full Text] [Related]
36. Osteoporotic vertebral fractures during pregnancy: be aware of a potential underlying genetic cause.
Campos-Obando N; Oei L; Hoefsloot LH; Kiewiet RM; Klaver CC; Simon ME; Zillikens MC
J Clin Endocrinol Metab; 2014 Apr; 99(4):1107-11. PubMed ID: 24423337
[TBL] [Abstract][Full Text] [Related]
37. Osteogenesis imperfecta.
Huber MA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):314-20. PubMed ID: 17223585
[TBL] [Abstract][Full Text] [Related]
38. Bone protective agents in children.
Wood CL; Ahmed SF
Arch Dis Child; 2018 May; 103(5):503-508. PubMed ID: 29066521
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
40. Osteogenesis imperfecta, current and future medical treatment.
Rauch F; Glorieux FH
Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):31-7. PubMed ID: 16278881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
